24
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Diagnosis and Treatment of Keloids and Hypertrophic Scars—Japan Scar Workshop Consensus Document 2018

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          There has been a long-standing need for guidelines on the diagnosis and treatment of keloids and hypertrophic scars that are based on an understanding of the pathomechanisms that underlie these skin fibrotic diseases. This is particularly true for clinicians who deal with Asian and African patients because these ethnicities are highly prone to these diseases. By contrast, Caucasians are less likely to develop keloids and hypertrophic scars, and if they do, the scars tend not to be severe. This ethnic disparity also means that countries vary in terms of their differential diagnostic algorithms. The lack of clear treatment guidelines also means that primary care physicians are currently applying a hotchpotch of treatments, with uneven outcomes. To overcome these issues, the Japan Scar Workshop (JSW) has created a tool that allows clinicians to objectively diagnose and distinguish between keloids, hypertrophic scars, and mature scars. This tool is called the JSW Scar Scale (JSS) and it involves scoring the risk factors of the individual patients and the affected areas. The tool is simple and easy to use. As a result, even physicians who are not accustomed to keloids and hypertrophic scars can easily diagnose them and judge their severity. The JSW has also established a committee that, in cooperation with outside experts in various fields, has prepared a Consensus Document on keloid and hypertrophic scar treatment guidelines. These guidelines are simple and will allow even inexperienced clinicians to choose the most appropriate treatment strategy. The Consensus Document is provided in this article. It describes (1) the diagnostic algorithm for pathological scars and how to differentiate them from clinically similar benign and malignant tumors, (2) the general treatment algorithms for keloids and hypertrophic scars at different medical facilities, (3) the rationale behind each treatment for keloids and hypertrophic scars, and (4) the body site-specific treatment protocols for these scars. We believe that this Consensus Document will be helpful for physicians from all over the world who treat keloids and hypertrophic scars.

          Related collections

          Most cited references119

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis

          Rei Ogawa (2017)
          Keloids and hypertrophic scars are caused by cutaneous injury and irritation, including trauma, insect bite, burn, surgery, vaccination, skin piercing, acne, folliculitis, chicken pox, and herpes zoster infection. Notably, superficial injuries that do not reach the reticular dermis never cause keloidal and hypertrophic scarring. This suggests that these pathological scars are due to injury to this skin layer and the subsequent aberrant wound healing therein. The latter is characterized by continuous and histologically localized inflammation. As a result, the reticular layer of keloids and hypertrophic scars contains inflammatory cells, increased numbers of fibroblasts, newly formed blood vessels, and collagen deposits. Moreover, proinflammatory factors, such as interleukin (IL)-1α, IL-1β, IL-6, and tumor necrosis factor-α are upregulated in keloid tissues, which suggests that, in patients with keloids, proinflammatory genes in the skin are sensitive to trauma. This may promote chronic inflammation, which in turn may cause the invasive growth of keloids. In addition, the upregulation of proinflammatory factors in pathological scars suggests that, rather than being skin tumors, keloids and hypertrophic scars are inflammatory disorders of skin, specifically inflammatory disorders of the reticular dermis. Various external and internal post-wounding stimuli may promote reticular inflammation. The nature of these stimuli most likely shapes the characteristics, quantity, and course of keloids and hypertrophic scars. Specifically, it is likely that the intensity, frequency, and duration of these stimuli determine how quickly the scars appear, the direction and speed of growth, and the intensity of symptoms. These proinflammatory stimuli include a variety of local, systemic, and genetic factors. These observations together suggest that the clinical differences between keloids and hypertrophic scars merely reflect differences in the intensity, frequency, and duration of the inflammation of the reticular dermis. At present, physicians cannot (or at least find it very difficult to) control systemic and genetic risk factors of keloids and hypertrophic scars. However, they can use a number of treatment modalities that all, interestingly, act by reducing inflammation. They include corticosteroid injection/tape/ointment, radiotherapy, cryotherapy, compression therapy, stabilization therapy, 5-fluorouracil (5-FU) therapy, and surgical methods that reduce skin tension.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            International clinical recommendations on scar management.

            Many techniques for management of hypertrophic scars and keloids have been proven through extensive use, but few have been supported by prospective studies with adequate control groups. Several new therapies showed good results in small-scale trials, but these have not been repeated in larger trials with long-term follow-up. This article reports a qualitative overview of the available clinical literature by an international panel of experts using standard methods of appraisal. The article provides evidence-based recommendations on prevention and treatment of abnormal scarring and, where studies are insufficient, consensus on best practice. The recommendations focus on the management of hypertrophic scars and keloids, and are internationally applicable in a range of clinical situations. These recommendations support a move to a more evidence-based approach in scar management. This approach highlights a primary role for silicone gel sheeting and intralesional corticosteroids in the management of a wide variety of abnormal scars. The authors concluded that these are the only treatments for which sufficient evidence exists to make evidence-based recommendations. A number of other therapies that are in common use have achieved acceptance by the authors as standard practice. However, it is highly desirable that many standard practices and new emerging therapies undergo large-scale studies with long-term follow-up before being recommended conclusively as alternative therapies for scar management.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Histopathological differential diagnosis of keloid and hypertrophic scar.

              Distinguishing hypertrophic scar (HS) from keloid histopathologically is sometimes difficult because thickened hyalinized collagen (keloidal collagen), the hallmark of keloid, is not always detectable and alpha-smooth muscle actin (alpha-SMA), a differentiating marker of HS, is variably expressed in both forms of scar. The aim of this study was to investigate additional distinguishing features to facilitate differentiation between keloid and HS. We compared various histologic features and the expression of alpha-SMA in 40 specimens of keloid and 10 specimens of HS. The features more commonly seen in keloids were: (a) no flattening of the overlying epidermis, (b) no scarring of the papillary dermis, (c) presence of keloidal collagen, (d) absence of prominent vertically oriented blood vessels, (e) presence of prominent disarray of fibrous fascicles/nodules, (f) presence of a tongue-like advancing edge underneath normal-appearing epidermis and papillary dermis, (g) horizontal cellular fibrous band in the upper reticular dermis, and (h) prominent fascia-like fibrous band. The last three features were found in keloid specimens only, including the ones lacking detectable keloidal collagen. Our study confirmed the diagnostic value of keloidal collagen, but it was only found in 55% of keloid specimens. Alpha-SMA expression was found in both HS (70%) and keloid (45%), thus it would not be a differentiating marker. In scars with no detectable keloidal collagen, the presence of the following feature(s) favors the diagnosis of keloid: non-flattened epidermis, non-fibrotic papillary dermis, a tongue-like advancing edge, horizontal cellular fibrous band in the upper reticular dermis, and prominent fascia-like band.
                Bookmark

                Author and article information

                Contributors
                r.ogawa@nms.ac.jp
                akitas@hf.rim.or.jp
                redstoneprs@gmail.com
                nonken@2001.jukuin.keio.ac.jp
                dohiprs@gmail.com
                toshi-116@nifty.com
                kkishi@sc.itc.keio.ac.jp
                trkono@gmail.com
                hmatsu-tki@umin.ac.jp
                muneuchi@nakatsu.saiseikai.or.jp
                mr-n-y-mura@muf.biglobe.ne.jp
                munetomonagao@max.odn.ne.jp
                dawndawn@hotmail.co.jp
                fumi@oita-u.ac.jp
                mamiko_prs@yahoo.co.jp
                ytosa@med.showa-u.ac.jp
                satokoy@kuhp.kyoto-u.ac.jp
                shin8113@nms.ac.jp
                n.inazu@thu.ac.jp
                t-kamo@ka2.so-net.ne.jp
                watanabe@kazki.co.jp
                kuripoyo@hotmail.co.jp
                Journal
                Burns Trauma
                Burns Trauma
                Burns & Trauma
                BioMed Central (London )
                2321-3868
                2321-3876
                27 December 2019
                27 December 2019
                2019
                : 7
                : 39
                Affiliations
                [1 ]ISNI 0000 0001 2173 8328, GRID grid.410821.e, Department of Plastic, Reconstructive and Aesthetic Surgery, , Nippon Medical School, ; 1-1-5 Sendagi Bunkyo-ku, Tokyo, 113-8603 Japan
                [2 ]ISNI 0000 0001 0672 2176, GRID grid.411497.e, Department of Plastic Surgery, Wound Repair and Regeneration, , Fukuoka University, ; Fukuoka, 814-0180 Japan
                [3 ]ISNI 0000 0004 0406 9101, GRID grid.459842.6, Department of Plastic Surgery, , Nippon Medical School Musashikosugi Hospital, ; 1-396 Kosugicho, Nakahara-ku, Kawasaki-shi, Kanagawa 211-8533 Japan
                [4 ]ISNI 0000 0004 1936 9959, GRID grid.26091.3c, Department of Plastic and Reconstructive Surgery, , Keio University School of Medicine, ; 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582 Japan
                [5 ]ISNI 0000 0001 2173 7691, GRID grid.39158.36, Department of Plastic and Reconstructive Surgery, Faculty of Medicine and Graduate School of Medicine, , Hokkaido University, ; Kita-15, Nishi-7, Kita-ku, Sapporo, 060-8638 Japan
                [6 ]ISNI 0000 0001 1516 6626, GRID grid.265061.6, Department of Plastic Surgery, , Tokai University School of Medicine, ; 4-1-1 Kitakaname, Hiratsuka, Kanagawa 259-1292 Japan
                [7 ]ISNI 0000 0001 0663 3325, GRID grid.410793.8, Department of Plastic and Reconstructive Surgery, , Tokyo Medical University, ; 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023 Japan
                [8 ]ISNI 0000 0004 0471 596X, GRID grid.416618.c, Department of Plastic and Reconstructive Surgery, , Osaka Saiseikai Nakatsu Hospital, ; 2-10-39 Shibata, Kita-ku, Osaka, 530-0012 Japan
                [9 ]ISNI 0000 0000 9613 6383, GRID grid.411790.a, Department of Plastic, Reconstructive and Aesthetic Surgery, , Iwate Medical University School of Medicine, ; 19-1 Uchimaru, Morioka, Iwate 020-8505 Japan
                [10 ]ISNI 0000 0004 0639 8726, GRID grid.412337.0, Department of Plastic Surgery, , Oita University Hospital, ; 1-1 Idaigaoka, Hasamamachi, Yufu-shi, Oita 879-5503 Japan
                [11 ]ISNI 0000 0004 1764 9041, GRID grid.412808.7, Department of Plastic Surgery, , Showa University Fujigaoka Hospital, ; 1-30 Fujigaoka, Aoba-ku, Yokohama, Kanagawa Japan
                [12 ]Department of Plastic and Reconstructive Surgery, Japanese Red Cross Fukui Hospital, 2-4-1 Tsukimi, Fukui, 918-8501 Japan
                [13 ]ISNI 0000 0004 0406 9101, GRID grid.459842.6, Division of Dermatology and Dermatopathology, , Nippon Medical School Musashikosugi Hospital, ; 1-396, Kosugicho, Nakahara-ku, Kawasaki-shi, Kanagawa 211-8533 Japan
                [14 ]GRID grid.440938.2, Faculty of Pharmaceutical Sciences, , Teikyo Heisei University, ; 4-21-2 Nakano, Nakano-ku, Tokyo, 164-8530 Japan
                [15 ]Wakamatsu-cho Mental and Skin Clinic, 9-4 Wakamatsu-cho, Shinjyuku-ku, Tokyo, 162-0056 Japan
                [16 ]ISNI 0000 0004 0616 2203, GRID grid.416279.f, Department of Radiation Oncology, , Nippon Medical School Hospital, ; Tokyo, 113-8603 Japan
                Author information
                http://orcid.org/0000-0003-3658-555X
                Article
                175
                10.1186/s41038-019-0175-y
                6933735
                31890718
                a2e95e4d-caf0-41ad-b415-824af616587c
                © The Author(s) 2019

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 23 July 2019
                : 14 October 2019
                Categories
                Review
                Custom metadata
                © The Author(s) 2019

                keloid,hypertrophic scars,pathological scars,guideline,pathology,surgery,radiotherapy,steroid,laser

                Comments

                Comment on this article